BRPI0414869A - compostos e composições como inibidores da proteìna quinase - Google Patents

compostos e composições como inibidores da proteìna quinase

Info

Publication number
BRPI0414869A
BRPI0414869A BRPI0414869-0A BRPI0414869A BRPI0414869A BR PI0414869 A BRPI0414869 A BR PI0414869A BR PI0414869 A BRPI0414869 A BR PI0414869A BR PI0414869 A BRPI0414869 A BR PI0414869A
Authority
BR
Brazil
Prior art keywords
compounds
compositions
protein kinase
kinase inhibitors
raf
Prior art date
Application number
BRPI0414869-0A
Other languages
English (en)
Inventor
Nathanael Schiander Gray
Jiqing Jiang
Yi Liu
Ruo Steensma
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of BRPI0414869A publication Critical patent/BRPI0414869A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS E COMPOSIçõES COMO INIBIDORES DA PROTEìNA QUINASE". A presente invenção refere-se a uma nova classe de compostos, composições farmacêuticas que compreendem tais compostos e processos para a utilização de tais compostos para tratar ou prevenir doenças ou distúrbios associados com a atividade anormal ou desregulada de quinases, particularmente doenças ou distúrbios que envolvem a ativação anormal das quinases Abl BCR-Abl, PDGF-R, Ick, SAPK2<244>, p38, TGF<225>, KDR, c-Kit, b-RAF, c-RAF, FLT1 e FLT4.
BRPI0414869-0A 2003-10-02 2004-10-01 compostos e composições como inibidores da proteìna quinase BRPI0414869A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50845003P 2003-10-02 2003-10-02
PCT/US2004/032597 WO2005030151A2 (en) 2003-10-02 2004-10-01 Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0414869A true BRPI0414869A (pt) 2006-11-28

Family

ID=34393249

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414869-0A BRPI0414869A (pt) 2003-10-02 2004-10-01 compostos e composições como inibidores da proteìna quinase

Country Status (9)

Country Link
US (2) US7569593B2 (pt)
EP (1) EP1670780A4 (pt)
JP (1) JP2007507540A (pt)
CN (1) CN100455579C (pt)
AU (1) AU2004275888B2 (pt)
BR (1) BRPI0414869A (pt)
CA (1) CA2540518A1 (pt)
MX (1) MXPA06003644A (pt)
WO (1) WO2005030151A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102325A1 (en) * 2004-04-20 2005-11-03 Ab Science Use of c-kit inhibitors for treating inflammatory muscle disorders including myositis and muscular dystrophy
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
PL2167498T3 (pl) * 2007-06-15 2011-03-31 Irm Llc Związki i kompozycje jako inhibitory ITPKB
EP2300013B2 (en) 2008-05-21 2024-11-13 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2010095227A1 (ja) * 2009-02-19 2010-08-26 富士通株式会社 新規化合物、並びに、結合阻害剤、抗アレルギー剤、抗喘息剤、及び抗炎症剤
JP5370472B2 (ja) * 2009-02-19 2013-12-18 富士通株式会社 新規化合物、並びに、結合阻害剤、抗アレルギー剤、抗喘息剤、及び抗炎症剤
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN109476629B (zh) * 2016-07-22 2022-04-15 先正达参股股份有限公司 脲和硫脲取代的双环衍生物作为杀有害生物剂
CN108103186B (zh) * 2018-02-28 2021-07-02 固安博健生物技术有限公司 诊断类风湿性关节炎和骨关节炎的分子标志物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) * 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
AU7629594A (en) 1993-07-21 1995-02-20 Smithkline Beecham Corporation Imidazoles for treating cytokine mediated disease
BR9506864A (pt) * 1994-02-04 1997-09-09 Smithkline Beecham Plc Processo para epoxidar olefinas proquirais e um catalisador para as mesmas e intermdiários para produzir o catalisador
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO1997035855A1 (en) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
JP2000504023A (ja) * 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
GB9713726D0 (en) * 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
US6207687B1 (en) * 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US7189745B1 (en) * 1999-11-22 2007-03-13 Smithkline Beecham Corporation Compounds
WO2002024680A1 (en) * 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Imidazole derivatives as raf kinase inhibitors
WO2002039954A2 (en) * 2000-11-20 2002-05-23 Smithkline Beecham Corporation Novel compounds
US20030165873A1 (en) * 2001-03-02 2003-09-04 Come Jon H. Three hybrid assay system

Also Published As

Publication number Publication date
US7569593B2 (en) 2009-08-04
US20090258910A1 (en) 2009-10-15
JP2007507540A (ja) 2007-03-29
AU2004275888B2 (en) 2008-09-18
WO2005030151A2 (en) 2005-04-07
EP1670780A4 (en) 2008-12-17
CN100455579C (zh) 2009-01-28
CN1860111A (zh) 2006-11-08
US20050209285A1 (en) 2005-09-22
CA2540518A1 (en) 2005-04-07
WO2005030151A3 (en) 2005-09-09
AU2004275888A1 (en) 2005-04-07
EP1670780A2 (en) 2006-06-21
MXPA06003644A (es) 2006-06-20

Similar Documents

Publication Publication Date Title
BRPI0414930A (pt) compostos e composições como inibidores de proteìnas cinases
BRPI0507668A (pt) compostos e composições como inibidores de proteìna cinase
BRPI0719797A8 (pt) Compostos e composições como inibidores de proteína cinase
BRPI0415210A (pt) compostos e composições como inibidores de proteìna cinase
BRPI0511978A (pt) compostos e composições como inibidores de proteìnas quinases
PL1896470T3 (pl) Pochodne pirolopirydynowe jako inhibitory kinazy białkowej
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
BRPI0815715A8 (pt) Compostos 5-(-4-(haloalcóxi)fenil)pirimidina-2-amina e composições como inibidores de quinases.
IL192557A (en) Imidazole derivatives are conserved and used as ptpase inhibitors
BRPI0414049A (pt) compostos e composições como inibidores de proteìna cinase
BRPI0413563A (pt) compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
UA97816C2 (en) Compounds modulating c-kit and/or c-fms activity and use thereof
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
BR0215429A (pt) Composto de fórmula i e seus usos, métodos de inibição da atividade e método de inibição da ativação de um receptor de monoamina, métodos de tratamento, método de identificação de polimorfismo genético e método de identificação de paciente
BR112014004465A2 (pt) compostos e composições como inibidores de pdgfr cinase
BR112012004453A8 (pt) composto inibidor de proteína quinase, sua composição farmacêutica e seu uso
BRPI0415467A (pt) compostos de 2-aminoariloxazol para o tratamento de doenças
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009004141A (es) Composiciones y metodos para modular receptores de c-kit y pdgfr.
MA31764B1 (fr) Composés et compositions en tant que modulateurs de l&#39;activité de gpr119
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
BR0306988A (pt) Piridazinonas substituìdas como inibidores de p38
MX2007012847A (es) Antagonistas de npy, preparacion y usos.
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
BRPI0812170A8 (pt) Moduladores de gama secretase

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 401/04, A61P 35/00, A61P 37/00, A61P 25/00

Ipc: C07D 401/04 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.